Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences (ARTL) generates news related to its clinical development programs targeting the endocannabinoid system for inflammatory and metabolic diseases. The company's announcements typically include updates on clinical trial progress, preclinical research findings, regulatory milestones, and corporate developments that impact its drug development pipeline.
Clinical trial updates represent a significant category of news for Artelo, as the biopharmaceutical company advances its drug candidates through various phases of human testing. These announcements may include trial initiations, patient enrollment milestones, interim data readouts, and final results from safety and efficacy studies. Each clinical update provides insight into whether the company's endocannabinoid-targeted therapies demonstrate the biological activity and safety profiles necessary for continued development.
Research publications and scientific presentations constitute another important news category. Artelo collaborates with academic institutions and research organizations, often publishing findings in peer-reviewed journals or presenting data at medical conferences. These publications establish scientific credibility and contribute to the broader understanding of endocannabinoid pharmacology and its therapeutic applications.
Corporate developments including financing transactions, partnership agreements, intellectual property milestones, and leadership appointments also generate newsworthy announcements. As a clinical-stage company requiring ongoing capital to fund operations, Artelo periodically announces equity offerings and private placements. Partnership announcements may signal validation of the company's scientific approach or provide access to additional resources for drug development.
This news coverage provides context for understanding Artelo's progress in advancing novel therapeutics through the complex biopharmaceutical development pathway. Following these updates helps track the company's clinical milestones, research collaborations, and financial position as it works toward potential regulatory approvals.
Artelo Biosciences (Nasdaq: ARTL) commented on the Dec 23, 2025 White House Executive Order creating a Medicare pilot for cannabidiol (CBD) reimbursement and structured data collection.
Artelo said the initiative could improve access and generate data to inform research and potential Medicaid expansion. The company highlighted ART12.11, its patented CBD–tetramethylpyrazine cocrystal, stating superior oral bioavailability, more consistent pharmacokinetics, and enhanced efficacy signals in preclinical anxiety and depression models. Artelo reported the Drug Enforcement Agency indicated ART12.11 would not be considered a controlled substance and said it is prepared to complete final steps to advance ART12.11 into human clinical trials.
Artelo Biosciences (Nasdaq: ARTL) announced a peer‑reviewed publication (Dec 3, 2025) reporting that intraperitoneal dosing of its proprietary FABP5 inhibitor SBFI103 produced robust anxiolytic and antidepressant‑like effects in a validated chronic‑stress rat model.
Key experimental findings include single‑dose reductions in anxiety‑ and depression‑like behaviors with no locomotion or memory deficits, increased hippocampal expression of endocannabinoid‑related receptors CB2, GPR55, TRPV1, prevention of stress‑linked declines in depression biomarkers, and blockade of chronic‑stress effects on hippocampal neurogenesis.
The company funded the research; authors controlled study design and conclusions. Artelo said the data strengthen the rationale to advance FABP5 inhibitors (including ART26.12) toward human studies.
Artelo Biosciences (Nasdaq: ARTL) reported Q3 2025 results and provided a business update on Nov 12, 2025. Key clinical highlights include interim Phase 2 CAReS results for ART27.13 showing mean +6.4% weight gain at top dose versus -5.4% on placebo and +4.2% lean body mass, plus a Notice of Allowance from the European Patent Office covering the intended commercial formulation through 2041.
Development progress: ART26.12 completed SAD with a MAD protocol being finalized; ART12.11 first-in-human expected 1H 2026 after MHRA guidance. Q3 financials: R&D $1.3M, G&A $1.8M, net loss $3.1M (loss per share $3.97), cash and investments $1.7M; gross equity proceeds of $0.4M (ATM) and $3.0M (public offering).
Artelo Biosciences (Nasdaq: ARTL) announced the publication on November 4, 2025 of a peer‑reviewed review, “The Emerging Role of Fatty Acid Binding Protein 3 (FABP3) in Cancers,” in Drug Discovery Today with lead author Dr. George Warren.
The article is the third in a trilogy on FABP isoforms 3, 5, and 7 and highlights evidence that FABP3 promotes tumorigenic processes via lipid metabolism, hypoxia, and ferroptosis. The review notes that both genetic and pharmacological inhibition of FABP3 showed therapeutic benefits in preclinical cancer models. Artelo says it maintains a portfolio of selective, dual, and pan FABP3/5/7 inhibitors and is advancing its lead program, ART26.12, targeting FABP5 for pain while exploring oncology opportunities.
Artelo Biosciences (Nasdaq: ARTL) named Mark Spring, CPA, as Chief Financial Officer, effective November 1, 2025.
Mr. Spring has served as a financial consultant to Artelo since December 2024 and brings 30 years of life‑sciences financial leadership, including interim CFO and CFO roles at multiple commercial and development‑stage companies and significant M&A and licensing experience. The appointment is presented as strengthening financial leadership as Artelo advances its clinical pipeline and corporate growth initiatives.
Artelo Biosciences (Nasdaq: ARTL) will present expanded clinical data on ART26.12 and interim Phase 2 data on ART27.13 at the 8th Annual Cannabinoid & Endocannabinoid Drug Development Summit on October 15–16, 2025 in Boston.
Key findings: ART26.12 single ascending dose study showed safety at single doses up to 1050 mg, predictable linear plasma exposure, and potential dosing flexibility in fed or fasted states. ART27.13 Phase 2 interim data in cancer anorexia showed treated patients (up to 1300 µg/day on average) gained >b>6% body weight versus placebo patients who lost an additional 5%, with a similar tolerability profile to earlier stages to date.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has completed its previously announced public offering, raising $2.0 million in gross proceeds. The offering consisted of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares to cover over-allotments. R.F. Lafferty & Co. served as the sole book-running manager for the offering, which was conducted under Artelo's existing shelf registration statement.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced the pricing of a $2.0 million public offering. The offering consists of 441,210 shares of common stock priced at $4.40 per share and pre-funded warrants to purchase up to 13,335 shares at $4.399 per warrant.
The company has granted underwriters a 45-day option to purchase up to an additional 68,181 shares. The offering, managed by R.F. Lafferty & Co. as the sole book-runner, is expected to close on October 1, 2025. The securities are being offered through a shelf registration statement previously filed with and declared effective by the SEC.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, has announced a proposed underwritten public offering of common stock and/or pre-funded warrants. The offering will be managed by R.F. Lafferty & Co., Inc. as the sole book-running manager.
The securities will be offered through a "shelf" registration statement on Form S-3 that was previously filed and declared effective by the SEC on July 14, 2023. The final terms, size, and completion of the offering will depend on market conditions.
Artelo Biosciences (Nasdaq: ARTL) presented positive interim Phase 2 CAReS data for ART27.13 at the 2025 Cancer Cachexia Society Conference. The drug, targeting cancer anorexia-cachexia syndrome (CACS), demonstrated significant benefits in key metrics:
Patients receiving the highest dose (1300 µg) achieved an average +6% weight gain over 12 weeks, while placebo patients lost ~5%. The treatment showed improvements in lean body mass and increased daily activity levels, confirmed through digital wearable data. The drug maintained a favorable safety profile with mostly mild to moderate adverse events and no serious drug-related incidents.
Professor Barry Laird from Oslo University Hospital presented the data, while the company engaged in partnering discussions to advance the program's commercial potential.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
